. Author manuscript; available in PMC: 2016 Nov 1.

Published in final edited form as: Photochem Photobiol. 2015 Oct 12;91(6):1444–1451. doi: 10.1111/php.12521

Table 1.

Summary of increases in FAS/FASL- and TRAIL-R1(DR4)/TRAIL expression post epigenetically enhanced photodynamic therapy (ePDT) as assessed by multispectral imaging analysis. The components of ePDT (methotrexate (MTX) and photodynamic therapy (PDT)) responsible for the increase are listed individually for each cell line.

CTCL Line	FAS Increase	FASL Increase	TRAIL-R1(DR4) Increase	TRAIL Increase
MyLa	^*	PDT	MTX, PDT	^*, MTX
Hut78	^*	PDT	MTX
HH	MTX	PDT	MTX, PDT	PDT
SZ4	MTX	PDT	MTX, PDT	^*
SeAx	^**	PDT	MTX, PDT

CTCL, cutaneous T-cell lymphoma; FAS, Fas cell surface death receptor; FASL, Fas cell surface death receptor ligand; TRAIL-R1(DR4), TRAIL receptor 1 (death receptor 4); TRAIL, tumor necrosis factor-related apoptosis-inducing ligand;

High baseline expression;

^**

FAS-null.